Clinical assays for human chorionic gonadotropin: What should we measure and how?

Clinical Chemistry

Volumn 55, Issue 11, 2009, Pages 1900-1904

  Gronowski, Ann M ^a   Sturgeon, Catharine ^b,c,d   Stenman, Ulf Håkan ^e   Braunstein, Glenn D ^f,g   Butch, Anthony W ^h,i   Cowan, David A ^j,k  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c UK National External Quality Assessment Service Proficiency Testing Center   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UCLA MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j Department of Forensic Science and Drug Monitoring ^*  (United States)

^k KING'S COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; DIAGNOSTIC AGENT; TUMOR MARKER;

CARBOXY TERMINAL SEQUENCE; DOPING; GLYCOSYLATION; HORMONE DETERMINATION; HUMAN; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NOTE; PREGNANCY; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TROPHOBLASTIC DISEASE; ARTICLE; FEMALE; INTERVIEW; METHODOLOGY; PREGNANCY TEST; STANDARD; SUBSTANCE ABUSE; TROPHOBLASTIC TUMOR; URINE;

CHORIONIC GONADOTROPIN; FEMALE; GESTATIONAL TROPHOBLASTIC NEOPLASMS; HUMANS; IMMUNOASSAY; MASS SPECTROMETRY; PREGNANCY; PREGNANCY TESTS; SUBSTANCE ABUSE DETECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 70449711160     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.133595     Document Type: Note

References (0)